Literature DB >> 15939976

Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole.

Matthias R Lemke1, H Michael Brecht, Juergen Koester, Peter H Kraus, Heinz Reichmann.   

Abstract

Anhedonia, a core symptom of depression, correlates with motor alterations in major depressive disorder and has been assumed to be frequent in depressed patients with Parkinson's disease (PD). In the present study, the authors assessed for the first time frequency of anhedonia in patients with idiopathic Parkinson's disease (N = 657) and the relationship of anhedonia and parkinsonian motor deficits during treatment with pramipexole. Mild depression was present in 47% of the patients and moderate to severe depression in 22%. Anhedonic individuals included 45.7% of all patients and 79.7% of depressed Parkinson's disease patients. Anhedonic Parkinson's disease patients had greater motor deficits, restrictions in activities of daily living, and depression compared to nonanhedonic patients. Frequency of anhedonia and depression was significantly reduced during treatment with pramipexole. Future studies should further investigate antianhedonic efficacy of dopamine agonists including pramipexole in depressed patients with Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15939976     DOI: 10.1176/jnp.17.2.214

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  36 in total

Review 1.  Clinical staging in the pathophysiology of psychotic and affective disorders: facilitation of prognosis and treatment.

Authors:  Trevor Archer; Richard M Kostrzewa; Tomas Palomo; Richard J Beninger
Journal:  Neurotox Res       Date:  2010-03-17       Impact factor: 3.911

Review 2.  Reconsidering anhedonia in depression: lessons from translational neuroscience.

Authors:  Michael T Treadway; David H Zald
Journal:  Neurosci Biobehav Rev       Date:  2010-07-11       Impact factor: 8.989

Review 3.  Molecular imaging and neural networks in impulse control disorders in Parkinson's disease.

Authors:  I Aracil-Bolaños; A P Strafella
Journal:  Parkinsonism Relat Disord       Date:  2015-08-12       Impact factor: 4.891

4.  Improving symptom control in early Parkinson's disease.

Authors:  Stuart H Isaacson; Robert A Hauser
Journal:  Ther Adv Neurol Disord       Date:  2009-11       Impact factor: 6.570

Review 5.  The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review.

Authors:  Albert F G Leentjens
Journal:  Drugs       Date:  2011-02-12       Impact factor: 9.546

Review 6.  Assessment and Management of Neuropsychiatric Symptoms in Parkinson's Disease.

Authors:  Christoph Mueller; Anto P Rajkumar; Yi Min Wan; Latha Velayudhan; Dominic Ffytche; Kallol Ray Chaudhuri; Dag Aarsland
Journal:  CNS Drugs       Date:  2018-07       Impact factor: 5.749

7.  Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study.

Authors:  Daniela Di Giuda; Giovanni Camardese; Anna Rita Bentivoglio; Fabrizio Cocciolillo; Arianna Guidubaldi; Lorella Pucci; Isabella Bruno; Luigi Janiri; Alessandro Giordano; Alfonso Fasano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-14       Impact factor: 9.236

Review 8.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

Review 9.  Parkinson disease: an update.

Authors:  Steven J Frucht
Journal:  Neurologist       Date:  2004-07       Impact factor: 1.398

Review 10.  Dopamine dysregulation syndrome. Hypothetical application of reward system stimulation for the treatment of anhedonia in Parkinson's disease patients.

Authors:  Tomoyoshi Kondo
Journal:  J Neurol       Date:  2008-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.